Health News Releases

  • Today March 21
January 24, 10:13
Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery
Masimo (NASDAQ: MASI) today announced the findings of a prospective, single-blinded, randomized controlled study published in the Journal of Anesthesia & Intensive Care Medicine in which Dr. Mona Moha
January 21, 13:20
IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio
Galderma will be showcasing the latest updates from across its portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris from January 26-28, 2023. Events will
January 20, 14:10
Chief Rabbi of Israel Affirms Aleph Farms’ Cultivated Steak is Kosher
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that Israeli Chief Rabbi, David Baruch Lau, has ruled its cultivate
January 20, 11:26
Kaneka expands GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A.
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: L
January 19, 14:30
TA Announces Strategic Growth Investment in Synokem Pharmaceuticals
TA Associates (“TA”), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (“Synokem” or “the Company”). Syn
January 19, 09:45
Agenda 2023: PQE Group Boosting Growth by Reinforcing Service Portfolio and Entering New Markets
It has been another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) with 32 offices worldwide. Recently named “Best Managed Company” by Deloitt
January 18, 10:10
Takeda Named Global Top Employer for Sixth Consecutive Year
Takeda (TSE:4502/NYSE:TAK) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® certification for 2023. In addition to the global certi
January 18, 09:25
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®) and bevacizumab in a
January 18, 09:20
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
The Top Employers Institute awarded Boehringer Ingelheim for the third year in succession a “Global Top Employer”, one of the world’s 15 best employers. The certification also highlights the company’s
January 17, 10:15
JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairma
January 13, 14:40
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with loca
January 12, 09:00
Global talent leader WilsonHCG acquires Personify to further expand its healthcare and life sciences talent solutions
WilsonHCG, a global talent leader, has announced the acquisition of Personify, an award-winning recruitment process outsourcing (RPO) provider. Personify specializes in the life sciences, healthcare,
January 11, 10:10
Limb Lengthening Expert Dr. Dror Paley Opens First Clinic in Middle East at UAE’s Burjeel Medical City
As part of its ongoing efforts to focus on complex care and pediatric sub-specialties, Burjeel Holdings, one of the leading private healthcare services providers in the MENA region, in collaboration w
January 10, 13:30
New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department
Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud Univ
January 10, 09:55
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address hi
January 10, 09:40
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for
January 09, 13:30
New Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality
Masimo (NASDAQ: MASI) today announced the findings of a before-and-after study published in PLoS ONE in which Dr. Ahmed Balshi and colleagues at King Saud Medical City in Riyadh, Saudi Arabia, evaluat
January 06, 14:40
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being stu
January 04, 11:43
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMi
January 04, 10:40
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluat
December 30, 2022 13:35
Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the third member of the RenMic
December 23, 2022 09:25
Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover no
December 21, 2022 09:45
Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the
December 20, 2022 10:05
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).
December 19, 2022 11:35
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an
December 16, 2022 16:00
CAS Introducing Transformational Capabilities to Accelerate Life Sciences Innovation
CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid dis
December 16, 2022 11:25
Artilysin®: Fearless Into the Post-antibiotic Era
The WHO has declared antibiotic resistances one of the Top 10 global threats to mankind. To counter this threat, Lysando AG has developed the so-called Artilysin® technology: Novel antimicrobial prote
December 14, 2022 16:45
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for
December 14, 2022 15:40
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly
December 14, 2022 14:25
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.[1] Spesolimab is a novel, selecti
December 14, 2022 10:00
AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting
AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health´s CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV
December 13, 2022 17:14
MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program
MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collab
December 13, 2022 14:00
Masimo Announces Limited Market Release of Sepsis Index
Masimo (NASDAQ: MASI) today announced the limited market release of Sepsis Index (Si™), an early warning indicator designed to help clinicians identify possible sepsis in patients remotely monitored w
December 13, 2022 11:30
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
Organon (NYSE: OGN), a global women’s healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon’s execu
December 13, 2022 10:52
GI CELL Enters Agreement with Optieum Biotechnologies
GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum Biotechnologies will provide GI CE
December 12, 2022 15:15
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
Takeda (TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Or
December 12, 2022 10:00
Takeda’s QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (T
December 09, 2022 14:32
ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor
ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medica
Eric Y. Kim, Principal Machine Learning Engineer of Bertis Bioscience
December 09, 2022 10:37
Bertis Reveals Research Results of AI-based Diagnosis Model with Proteomic Mass Spectrometry Data
Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022,
Ajoy Karna, CFO, Covetrus
December 09, 2022 09:30
Covetrus Names Ajoy Karna as Chief Financial Officer
Covetrus®, a global leader in animal-health technology and services, today announced the appointment of Ajoy Karna as executive vice president and chief financial officer. Karna succeeds Matthew Fouls
Michael Prosser, Chief Business Officer, Crown Bioscience
December 09, 2022 09:15
Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
Crown Bioscience, Inc, a JSR Life Sciences Company, and ERS Genomics Limited (‘ERS’) have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, whi
December 09, 2022 09:00
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first immunological results of its PDC-LUNG-101
December 08, 2022 10:20
Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience
Medidata, a Dassault Systèmes company, launched a new patient-centric native myMedidata app, designed to provide trial participants with another option for a seamless platform experience and a single
December 08, 2022 09:40
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo
December 07, 2022 14:50
Affiliates of ZCG Acquire Universal Marine Medical Supply International
Z Capital Partners, L.L.C., the private equity fund management arm of Z Capital Group, L.L.C. (“ZCG”), a leading privately held merchant bank, today announced that affiliates of ZCG have acquired Univ
December 05, 2022 09:40
Deadline for Aster Guardians Global Nursing Award 2023 worth US $250,000 extended until 12th December
Aster Guardians Global Nursing Award, an initiative by leading healthcare provider Aster DM Healthcare to recognize the contribution of nurses to the community, has announced an extension of deadline
December 02, 2022 15:25
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevant Oncology Drug Development
Crown Bioscience, a JSR Life Sciences company and Contract Research Organization (CRO), has announced the publication of its review paper entitled: Translational and Clinical Relevance of PDX-Derived
December 02, 2022 14:55
Sermo Survey Finds Opportunity to Educate General Care Physicians on PrEP to Increase Patient Adoption Nearly Half of General Care Physicians Reported They Do Not Have Enough Knowledge About PrEP Options to Discuss with Patients
Timed to World AIDS Day, Sermo, a physician-first online community and leader in global HCP insights, released a new survey that found 46% of general care physicians including PCPs, OB-GYNs, and pedia
December 02, 2022 09:20
Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic
Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicat
December 01, 2022 09:50
AGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbH
AGIC Capital (“AGIC”), a growth-oriented private equity firm with $2.2 billion of assets under management, today announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH (“ATEC” or “
25 per page50 per page75 per page100 per page